- Home
- GDO vs UNCY Comparison
GDO vs UNCY Comparison
Compare GDO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDO
- UNCY
- Stock Information
- Founded
- GDO 2009
- UNCY 2016
- Country
- GDO United States
- UNCY United States
- Employees
- GDO N/A
- UNCY N/A
- Industry
- GDO Finance Companies
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- GDO Finance
- UNCY Health Care
- Exchange
- GDO Nasdaq
- UNCY Nasdaq
- Market Cap
- GDO 84.5M
- UNCY 62.7M
- IPO Year
- GDO N/A
- UNCY 2021
- Fundamental
- Price
- GDO $11.27
- UNCY $0.60
- Analyst Decision
- GDO
- UNCY Strong Buy
- Analyst Count
- GDO 0
- UNCY 4
- Target Price
- GDO N/A
- UNCY $5.50
- AVG Volume (30 Days)
- GDO 39.4K
- UNCY 1.1M
- Earning Date
- GDO 01-01-0001
- UNCY 03-27-2025
- Dividend Yield
- GDO 9.81%
- UNCY N/A
- EPS Growth
- GDO N/A
- UNCY N/A
- EPS
- GDO N/A
- UNCY N/A
- Revenue
- GDO N/A
- UNCY N/A
- Revenue This Year
- GDO N/A
- UNCY N/A
- Revenue Next Year
- GDO N/A
- UNCY N/A
- P/E Ratio
- GDO N/A
- UNCY N/A
- Revenue Growth
- GDO N/A
- UNCY N/A
- 52 Week Low
- GDO $11.21
- UNCY $0.20
- 52 Week High
- GDO $13.04
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- GDO 44.76
- UNCY 44.45
- Support Level
- GDO $11.20
- UNCY $0.51
- Resistance Level
- GDO $11.30
- UNCY $0.64
- Average True Range (ATR)
- GDO 0.08
- UNCY 0.05
- MACD
- GDO 0.02
- UNCY -0.01
- Stochastic Oscillator
- GDO 62.16
- UNCY 40.91
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.